Alpha 2.0
Login Register
» Authors » Carlo Cattrini

Carlo Cattrini

Explore the profile of Carlo Cattrini including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 50
Citations 495
Followers 0
Related Specialties
Oncology
Urology
Pharmacology
Top 10 Co-Authors
Carlo Messina
Francesco Boccardo
Sebastiano Buti
Orazio Caffo
Elisa Zanardi
Alessia Mennitto
Giandomenico Roviello
Giuseppe Fornarini
Matteo Santoni
Alessandra Gennari
Published In
Cancers (Basel)
Ther Adv Urol
Clin Genitourin Cancer
Anticancer Drugs
Cancer Immunol Immunother
Affiliations
Soon will be listed here.
Recent Articles
1.
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study
Roviello G, Molina-Cerrillo J, Massari F, Cerbone L, Fiala O, Fornarini G, et al.
Cancer Immunol Immunother . 2025 Jan; 74(2):65. PMID: 39752009
Introduction: Renal cell carcinoma (RCC) is one of the most common types of urogenital cancer. The introduction of immune-based combinations, including dual immune-checkpoint inhibitors (ICI) or ICI plus tyrosine kinase...
2.
Development and Validation of Prognostic Model for Metastatic Castration-Resistant Prostate Cancer Patients Treated With First-Line Abiraterone or Enzalutamide
Caffo O, Basso U, Cattrini C, Ermacora P, Maruzzo M, Alberti M, et al.
Clin Genitourin Cancer . 2024 Dec; 23(1):102265. PMID: 39662149
Introduction: Over the years, several prognostic models were developed in patients receiving chemotherapy for metastatic castration resistant prostate cancer (mCRPC), while data on androgen-receptor signaling inhibitors (ARSI) in a real-world...
3.
Serum Biomarkers to Dynamically Predict the Risk of Cardiovascular Events in Patients under Oncologic Therapy. A Multicenter Observational Study
Provinciali N, Piccininno M, Siri G, Gennari A, Antonucci G, Ricci D, et al.
Rev Cardiovasc Med . 2024 Aug; 25(7):256. PMID: 39139415
Background: Serum biomarkers have been investigated as predictive risk factors for cancer-related cardiovascular (CV) risk, but their analysis is limited to their baseline level rather than their overtime change. Besides...
4.
Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors
Mokbel S, Baciarello G, Lavaud P, Omlin A, Calabro F, Cathomas R, et al.
Cancers (Basel) . 2024 Apr; 16(8). PMID: 38672547
Background: Immune checkpoint inhibitors (ICIs) improve overall survival (OS) in advanced/metastatic urothelial cancer (a/mUC) patients. Preliminary evidence suggests a prognostic role of inflammatory biomarkers in this setting. We aimed to...
5.
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients
Buti S, Olivari A, Masini C, Bimbatti D, Sartori D, Ermacora P, et al.
Ther Adv Urol . 2024 Apr; 16:17562872241244574. PMID: 38638242
Background: The treatment of heavily pretreated patients with metastatic renal cell carcinoma (mRCC) represents an unmet medical need and is still challenging. Objectives: The primary objective was to assess the...
6.
Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients
Cattrini C, Manfredi M, Barboro P, Ghirimoldi M, Mennitto A, Martini V, et al.
Sci Rep . 2023 Oct; 13(1):17791. PMID: 37853018
Emerging evidence highlights the potential prognostic relevance of circulating lipids in metastatic castration-resistant prostate cancer (mCRPC), with a proposed 3-lipid signature. This study aims to analyze the lipidomic profiles of...
7.
TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis
Pisano C, Turco F, Arnaudo E, Fea E, Vanella P, Ruatta F, et al.
Clin Genitourin Cancer . 2023 Oct; 22(2):56-67.e16. PMID: 37798164
Background: Treatment of metastatic hormone-sensitive prostate cancer (mHSPC) dramatically changed. PEACE-1 and ARASENS trials established triplet therapy efficacy. Identifying prognostic factors supporting treatment choice is pivotal. Methods: TEAM is an...
8.
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score
Mazzaschi G, Lazzarin A, Santoni M, Trentini F, De Giorgi U, Brighi N, et al.
Front Biosci (Elite Ed) . 2023 Sep; 15(3):20. PMID: 37743233
Background: The advent of immune checkpoint inhibitors (ICIs) has revolutionized the metastatic renal cell carcinoma (mRCC) therapeutic landscape. Nevertheless, tyrosine-kinase inhibitors (TKIs) targeting the vascular endothelial growth factor (VEGF) axis...
9.
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study
Fiala O, Buti S, Takeshita H, Okada Y, Massari F, Palacios G, et al.
Cancer Immunol Immunother . 2023 Sep; 72(11):3665-3682. PMID: 37676282
Background: Concomitant medications may potentially affect the outcome of cancer patients. In this sub-analysis of the ARON-2 real-world study (NCT05290038), we aimed to assess the impact of concomitant use of...
10.
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis
Messina C, Giunta E, Signori A, Rebuzzi S, Banna G, Maniam A, et al.
Eur Urol Oncol . 2023 Aug; 7(2):179-188. PMID: 37574390
Context: PARP inhibitors (PARPi) are established treatments for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) deficiency after androgen receptor signalling inhibitor (ARSI) failure. New PARPi + ARSI...